AI Regulation: EU Network Announces Four-Year Action Plan
Multiple guidance documents, a regulatory sandbox, and the creation of an “observatory” to monitor the emergence of new technologies are some of the actions being considered by the European medicines regulatory network under its AI regulatory system workplan.
You may also be interested in...
Guardrails protecting the public from artificial intelligence and machine learning systems are under development in the US and internationally. Whether they will inhibit global pharmaceutical manufacturers remains an open question that is sure to be discussed in the months and years ahead.
With the EU’s AI Act set to enter into force early this year, a life sciences lawyer tells the Pink Sheet how pharmaceutical firms could be affected by the landmark legislation in areas such as clinical trial recruitment and drug dose personalization.
A two-day workshop saw EU policymakers and regulators meet with dozens of representatives from the pharmaceutical, health and medtech industries to discuss the future of regulating AI in medicine and its uses in the medicinal product lifecycle.